Twist Bioscience
Twist Bioscience manufactures synthetic DNA and gene libraries for research, diagnostics, and drug discovery.
The call
Twist keeps growing on AI-driven gene orders, but cash keeps shrinking while Danaher-backed IDT builds competing synthesis deals.
Twist Bioscience manufactures synthetic DNA that AI companies use to test new drug candidates. The company has built real advantages through its manufacturing technology and accuracy, which competitors like IDT (owned by Danaher) and newer startups like DNA Script and Ansa Biotechnologies cannot easily copy. The big question is whether Twist's lab work will become a commoditized service that any vendor can provide, or whether it becomes truly locked in as the trusted partner for AI drug discovery data, especially as the market gets crowded with more synthetic DNA makers chasing the same AI customers.
Why
01
AI pressure: AI drug-design platforms (AWS Bio Discovery, generative sequence tools). AI-designed sequences drove over $25M in new orders in FY25, but that same volume lets cheaper synthesis rivals bid for the same work. Could AI do the core job? Unlikely.
02
Bigger players: IDT (Integrated DNA Technologies, owned by Danaher). IDT has shipped partnerships with Elegen and Ansa Biotechnologies aimed at the same complex-gene orders Twist relies on. Could a giant copy it? Probably.
03
What protects it. Its silicon-chip synthesis platform, Wilsonville factory, and 150+ patents produce genes at 99.5% accuracy, a combination rivals have not matched at scale.
What would change this call
IDT, Elegen, or Ansa announces a named AI-drug-discovery customer win (e.g. Bayer, Broad, AWS). Would show Twist losing share in the AI-discovery segment it depends on for growth.
Twist's Q3 FY26 earnings (Aug 3, 2026) therapeutics segment growth and gross margin trend. Reveals whether characterization services are commoditizing or holding pricing power.
Twist announces a dilutive capital raise before reaching cash-flow breakeven. Would signal the cash runway is tightening faster than growth can offset.
Twist's Q3 FY26 earnings (Aug 3, 2026) therapeutics segment growth and gross margin trend. Reveals whether characterization services are commoditizing or holding pricing power.
Twist announces a dilutive capital raise before reaching cash-flow breakeven. Would signal the cash runway is tightening faster than growth can offset.
Key numbers
- FY2025 revenue $376.6M, up 20% year over year
- FY2025 net loss $77.7M, down from $208.7M prior year
- Cash fell from $232.4M to $171.7M in two quarters
Named risks
- Continued net losses and declining cash ($232.4M to $171.7M in 8 months) without clear breakeven timeline.
- IDT (Danaher-backed) and enzymatic-synthesis startups Elegen and Ansa directly targeting Twist's Complex Genes segment.
- Characterization/wet-lab services could face commoditization and pricing pressure as more vendors chase AI-discovery volume.
- Dependence on AWS partnership exclusivity and marquee accounts (Bayer, Broad, MSK) that rivals could win instead.
- China exposure minimal (~1% of FY2025 revenue) limits growth diversification but also limits geopolitical risk.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| IDT (Integrated DNA Technologies, Danaher-owned) | contesting | Partnered with Elegen (Mar 2025) and Ansa Biotechnologies to compete on clonal genes, Twist's Complex Genes segment |
| Ginkgo Bioworks | contesting | Former largest customer turned partner/competitor; revised licensing agreement May 2025 for long-DNA tech |
| GenScript Biotech | contesting | Major China-based synthetic gene supplier competing in same market, per 2026-03-09 industry review |
| DNA Script | contesting | Enzymatic desktop DNA synthesis positioned as alternative to Twist's silicon platform (vendor-claimed) |
| AWS Bio Discovery / AI design platforms | gaining on | AI foundation models now generate candidate sequences upstream, narrowing Twist's role to wet-lab synthesis (Apr 2026) |
Questions people ask
- Is Twist Bioscience profitable in 2026?
- No. Twist posted a FY2025 net loss of $77.7 million (narrowed from $208.7 million in FY2024, aided by a divestiture gain), and Q2 FY2026 EPS was -$0.71, missing estimates, with cash down from $232.4M to $171.7M by May 2026.
- Could AI replace Twist Bioscience?
- Unlikely to fully replace it. AI models (like AWS Bio Discovery, used by Memorial Sloan Kettering to design 300,000 antibody candidates in April 2026) generate sequences but still need Twist's physical silicon-based synthesis platform and Wilsonville, Oregon factory to manufacture and test them.
- Who is Twist Bioscience's biggest competitor?
- Integrated DNA Technologies (IDT), owned by Danaher, is the top rival, having partnered with Elegen in March 2025 and with Ansa Biotechnologies to compete directly in clonal gene synthesis, Twist's core Complex Genes segment.
- Is Twist Bioscience a safe company to join in 2026?
- Financially it is growing fast, FY2025 revenue hit $376.6 million (+20%), and FY2026 guidance was raised twice to $442-447 million by May 2026, but the company remains unprofitable and headcount growth is modest relative to revenue, per its Sept 2025 filing showing 979 employees.
- How is Twist Bioscience benefiting from the AI drug discovery boom?
- Twist reported AI-drug-discovery order growth of more than $25 million versus FY2024, and its therapeutics/biopharma revenue grew about 55% year over year in Q2 FY2026 (reported May 4, 2026), driven partly by the AWS Amazon Bio Discovery partnership launched in April 2026.
- What is Twist Bioscience's revenue guidance for fiscal 2026?
- Initial FY2026 guidance issued in November 2025 was $425-435 million; it was raised to $435-440 million after Q1 (Feb 2026) and again to $442-447 million (+17-19% YoY) after Q2 results on May 4, 2026.
Timeline
- 2026-07-24Twist market cap reaches ~$5.75-5.76 billion, shares trading near $90-92
- 2026-05-08Twist announces LenioBio collaboration integrating cell-free protein expression for AI drug discovery
- 2026-05-04Q2 FY2026 results: revenue $110.7M (+19.3% YoY), EPS -$0.71 miss, guidance raised to $442-447M
- 2026-04-15AWS launches Amazon Bio Discovery platform with Twist and Ginkgo as wet-lab synthesis partners
- 2026-02-01Twist raises FY2026 revenue guidance to $435-440M after Q1 results
- 2025-11-14FY2025 results: revenue $376.6M (+20%), net loss $77.7M, initial FY2026 guidance $425-435M issued
- 2025-09-30FY2025 ends: 979 employees, cash position $232.4 million
- 2025-03-01Rival IDT partners with Elegen for clonal genes up to 15,000 bp, directly targeting Twist's segment
- 2022-02-01Twist completes $250 million follow-on raise led by Capital World Investors
- 2018-10-01Twist Bioscience IPOs on Nasdaq, raising approximately $70 million
Revision history
24 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Twist Q4/FY25 press release (2025-11-14)
- Twist Bioscience Reframes Revenue Reporting as AI-Based Drug Discovery Boosts Business (2025-11-14)
- Twist Bioscience (TWST) Earnings Call Transcripts (2026-06-01)
- Twist Bioscience (TWST) Earnings Date and Reports 2026 (2026-07-19)
- Twist Bioscience (TWST) Earnings Dates, Call Summary & Reports (2026-06-30)
- Twist Bioscience Corp (TWST) Q4 2025 Earnings Call Highlights (2025-11-14)
- gurufocus.com (2026-07-24)
- Twist Bioscience - Headcount, Funding & Open Jobs (2026-07-18)
- Twist Bioscience (TWST) Number of Employees (2025-09-29)
- Amazon Bio Discovery Launch Boosts Shares of Wet-Lab Partners Twist Bioscience, Ginkgo Bioworks (2026-04-15)
- LenioBio and Twist Bioscience Enter into a Collaboration (2026-05-08)
- Why Twist Bioscience's complex genes offering is a bet on AI-driven protein design (2026-05-17)